Concepedia

Jeremy Bjelajac

JB

Statistics

Publications

4

Citations

397

H-Index

4

Active since

2022

Affiliations

Stanford Medicine(Current)

Stanford University

Parker Institute for Cancer Immunotherapy

Jeremy Bjelajac is an author at Stanford Medicine specializing in cancer immunology, immunology, and life sciences.

ORCID

Publications per year

2022–2024

4

Publications

4

Enhanced T cell effector activity by targeting the Mediator kinase module

Katherine A. Freitas, Julia A. Belk, Elena Sotillo et al. · Science · 2022 · 142 citations · Full text

, , +17

A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells

Victor Tieu, Elena Sotillo, Jeremy Bjelajac et al. · Cell · 2024 · 113 citations · Full text

, , +17

Engineered CD47 protects T cells for enhanced antitumour immunity

Sean A. Yamada‐Hunter, Johanna Theruvath, Brianna J. McIntosh et al. · Nature · 2024 · 113 citations · Full text

, , +17

Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche

Daniel Haensel, Bence Dániel, Sadhana Gaddam et al. · Nature Communications · 2023 · 29 citations · Full text

, , +17

1–4 of 4